Aurobindo Pharma receives three ANDA approvals from USFDA for Atomoxetine Hydrochloride Capsules, Ribavirin Tablets and Ribavirin Capsules

Aurobindo Pharma Limited is pleased to announce that it has received the tentative approval for Atomoxetine Hydrochloride Capsules 10mg, 18mg , 25mg , 40mg, 60mg, 80mg and 100mg and final approvals for Ribavirin Tablets 200mg and Ribavirin Capsules 200mg from the US Food & Drug Administration (USFDA).

Atomoxetine Hydrochloride Capsules 10mg, 18mg, 25mg, 40mg, 60mg, 80mg and 100mg are generic equivalent to Strattera® 10mg, 18mg, 25mg, 40mg, 60mg, 80mg and 100mg of Eli Lily and Company and contains Paragraph IV certification with first-to-file status. Aurobindo shares 180 days exclusivity with other generic companies subject to the final approval and launch based on the pending litigation with Eli Lilly.

Atomoxetine Hydrochloride Capsules is indicated for the treatment of attention-deficit/ hyperactivity disorder (ADHD) in children aged 6 and older, teens, and adults and falls under the neurological (CNS) segment. The product has a market size of approximately US$ 500 million for the twelve months ending March 2009 according to Newport.

Ribavirin Tablets 200mg is generic equivalent to Copegus® Tablets 200mg of Hoffman La Roche Inc and Ribavirin Capsules 200mg is generic equivalent to Rebetol® Capsules 200mg of Schering Corporation. Ribavirin Tablets and Capsules are antiviral agents indicated in the treatment for the treatment of adults with chronic Hepatitis C Virus who have compensated liver disease and have not previously been treated with interferon alpha. The products has a market size of approximately US$ 90 million for the twelve months ending March 2009 according to Newport and will be launched shortly.

Aurobindo now has a total of 105 ANDA approvals (76 Final approvals and 29 Tentative approvals) from USFDA.

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/ product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterological, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 100 countries..

For further information, please contact:
Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com